SMTL ID : 3fdn.1

Structure-based drug design of novel Aurora kinase A inhibitors: Structure basis for potency and specificity

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x MMH: N-[3-(acetylamino)phenyl]-5-{(2E)-2-[(4-methoxyphenyl)methylidene]hydrazino}-3-methyl-1H-pyrazole-4-carboxamide(Non-covalent)

MMH.1: 15 residues within 4Å: Chain A: R.15, L.17, G.18, V.25, A.38, L.72, L.88, E.89, Y.90, A.91, P.92, G.94, T.95, R.98, L.141 16 PLIP interactions: 16 interactions with chain A Hydrophobic interactions: A:L.17, A:V.25, A:A.38, A:L.72, A:L.88, A:T.95, A:R.98, A:L.141 Hydrogen bonds: A:R.15, A:R.15, A:A.91, A:A.91, A:A.91, A:T.95 Water bridges: A:T.95 pi-Cation interactions: A:R.15

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Coumar, M.S. et al., Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. J.Med.Chem. (2009)

Release Date

2009-09-15

Peptides

Serine/threonine-protein kinase 6: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Serine/threonine-protein kinase 6

Related Entries With Identical Sequence